CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT06084533
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • [11C]-CS1P1 — DRUG
    Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.

Study Details

Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.

Key Dates

Start date
Jan 10, 2024
Status verified
Mar 2026
Primary completion
Feb 1, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
80 participants (estimated)

Arms

  • Arm: Parkinson Disease
  • Arm: Healthy Control

Primary Outcome Measure

PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease. [ Time Frame: At the time of PET scan ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63105-

Find similar trials in St Louis, MO

Related Studies